EC licenses MSD’s immunotherapy KEYTRUDA (pembrolizumab) for the treatment of advanced melanoma

MSD (known as Merck & Co Inc. in the United States and Canada) has announced that the European Commission has granted a marketing authorisation for KEYTRUDA® (pembrolizumab) as monotherapy for...